Rinvoq ER 15 MG tablet UU 30S
Ended Awarded
- Contract number
- SPE2DB25FNHGT
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,098
Award facts
- Contract value 100% obligated
- $4,097.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $4,097.72 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packaging) with an ultimate completion date of May 28, 2025. This non-set-aside, firm fixed price contract was competitively awarded and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and other government medical supply networks.
This delivery order falls under AmerisourceBergen's comprehensive $999,999,999 pharmaceutical prime vendor contract with DLA Troop Support Medical (designated SPE2DX) running through December 2026, which enables the company to supply a broad range of pharmaceutical products and medical supplies globally to support military healthcare programs. RINVOQ (upadacitinib) is a Janus kinase inhibitor used in the treatment of rheumatoid arthritis and other autoimmune conditions, reflecting the types of specialty medications the vendor provides through its federal contract portfolio. The award demonstrates AmerisourceBergen's continued capability to meet federal procurement requirements through competitive bidding and its established role as a primary pharmaceutical supplier within the DLA's medical supply chain.
Quick answers
Who was awarded contract SPE2DB25FNHGT?
SPE2DB25FNHGT was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on May 27, 2025.
How much is contract SPE2DB25FNHGT worth?
The government has obligated $4,098 on SPE2DB25FNHGT.
Is contract SPE2DB25FNHGT an order under another contract?
Yes. SPE2DB25FNHGT is a delivery order under SPE2DB20D1004, an indefinite delivery contract.
Was contract SPE2DB25FNHGT competed?
The extent of competition for SPE2DB25FNHGT was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award